Record: 21

11/15/2021

Company Report

Pages: 7

3Q Recap; Type B Meeting With FDA Around YE21; New Phase 3 uUTI Trial Start Expected in 1H22

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Record: 22

10/11/2021

Industry Report

Pages: 8

IDWeek 2021: Poster Presentation Highlights Within Our Antibiotics Coverage Space

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Record: 23

09/29/2021

Daily Note

Pages: 3

Type A Meeting Offers Path Forward for Sulopenem via New Phase 3 Study; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Record: 24

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ITRM

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Record: 25

08/16/2021

Company Report

Pages: 7

2Q21 Recap: Type A Meeting With FDA in Coming Weeks to Determine Sulopenem''s Future; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Record: 26

08/02/2021

Company Report

Pages: 2

Termination of Sell Side Coverage-Hold

Provider: G.RESEARCH, LLC

Analyst: Research Department

Price: 10.00

Record: 27

07/27/2021

Company Report

Pages: 2

No Surprise in CRL

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Record: 28

07/26/2021

Company Report

Pages: 6

CRL Requests a New Sulopenem Trial; Downgrade to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Record: 29

07/02/2021

Daily Note

Pages: 3

FDA Flags Deficiencies in Sulopenum NDA; Approval on July 25 PDUFA at Risk; Maintain Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Record: 30

07/02/2021

Company Report

Pages: 2

Sulopenem Gets the Kiss of Death

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Record: 31

06/21/2021

Company Report

Pages: 3

Watching for a Run-up-Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Record: 32

05/28/2021

Company Report

Pages: 2

Raising to Hold on Trading Impact of Nixed AdCom- Sell

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Record: 33

05/28/2021

Company Report

Pages: 8

Avoiding the Distracting Whipsaw of Agency Communications, We Remain Focused on July 25 PDUFA; 1Q Recap; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Record: 34

05/17/2021

Company Report

Pages: 2

Q1 Results: AdCom Still in Limbo

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Record: 35

04/13/2021

Company Report

Pages: 2

AdCom Delay Does Sulopenem No Favors

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Record: 36

03/16/2021

Company Report

Pages: 2

Save the Date: AdCom Planned for June 2

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Record: 37

03/15/2021

Company Report

Pages: 7

4Q Recap: A Clear Line of Sight to a Significant Opportunity in uUTI; Upgrading to Buy, $2.50 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Record: 38

02/22/2021

Industry Report

Pages: 10

Revisiting Small Cap Antibiotics

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 25.00

Record: 39

01/28/2021

Company Report

Pages: 2

Sulopenem Accepted, AdCom Expected- Sell

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Record: 40

01/26/2021

Daily Note

Pages: 3

Sulopenem NDA for uUTI Accepted With July 25 PDUFA Date; Awaiting Commercial Plan to Solidify; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00